Abstract
Tumor cells depend on and are able to modulate the tumor stroma establishing a permissive and supportive environment of their own. Targeting the tumor stroma has evolved as a novel concept that has attracted attention of cancer researchers aiming at the treatment of metastatic cancer. The novel paradigm is that modulating the stroma will possibly not cure the cancer, but will make it a manageable disease for long periods of time by prohibiting the cancer from growing beyond a certain mass. Accordingly, in the last years, a multitude of stroma-targeting agents were developed comprising either classic small molecule drugs (e.g. sorafenib, an inhibitor of multiple tyrosine kinases) or recombinant antibodies (e.g. anti-VEGF) for targeting of tumor angiogenesis. Apart from these specifically targeted drugs, some well established drugs, primarily designed for non-oncologic diseases, have revealed antitumor activity on the basis of nuclear receptor modulation unfolding pleiotropic biological effects including stroma modulation. Peroxisome Proliferator Activated Receptor (PPAR) agonists, particularly thiazolidinedione derivatives such as pioglitazone and ciglitazone, are promising examples as they exert both a direct antitumoral and a broad spectrum of anti-stromal, antiangiogenic and immuno-modulating activities. This review will focus on the stroma-mediated anticancer activities of PPAR agonists.
Keywords: PPAR, stroma, cancer, targeting, biomodulation, metronome chemotherapy, thiazolidinedione
Anti-Cancer Agents in Medicinal Chemistry
Title: Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists
Volume: 9 Issue: 7
Author(s): Annika Bundscherer, Albrecht Reichle, Christian Hafner, Stefanie Meyer and Thomas Vogt
Affiliation:
Keywords: PPAR, stroma, cancer, targeting, biomodulation, metronome chemotherapy, thiazolidinedione
Abstract: Tumor cells depend on and are able to modulate the tumor stroma establishing a permissive and supportive environment of their own. Targeting the tumor stroma has evolved as a novel concept that has attracted attention of cancer researchers aiming at the treatment of metastatic cancer. The novel paradigm is that modulating the stroma will possibly not cure the cancer, but will make it a manageable disease for long periods of time by prohibiting the cancer from growing beyond a certain mass. Accordingly, in the last years, a multitude of stroma-targeting agents were developed comprising either classic small molecule drugs (e.g. sorafenib, an inhibitor of multiple tyrosine kinases) or recombinant antibodies (e.g. anti-VEGF) for targeting of tumor angiogenesis. Apart from these specifically targeted drugs, some well established drugs, primarily designed for non-oncologic diseases, have revealed antitumor activity on the basis of nuclear receptor modulation unfolding pleiotropic biological effects including stroma modulation. Peroxisome Proliferator Activated Receptor (PPAR) agonists, particularly thiazolidinedione derivatives such as pioglitazone and ciglitazone, are promising examples as they exert both a direct antitumoral and a broad spectrum of anti-stromal, antiangiogenic and immuno-modulating activities. This review will focus on the stroma-mediated anticancer activities of PPAR agonists.
Export Options
About this article
Cite this article as:
Bundscherer Annika, Reichle Albrecht, Hafner Christian, Meyer Stefanie and Vogt Thomas, Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (7) . https://dx.doi.org/10.2174/187152009789056912
DOI https://dx.doi.org/10.2174/187152009789056912 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances on the Antiatherogenic Effects of HDL-Derived Proteins and Mimetic Peptides
Current Pharmaceutical Design Impact of Patient Knowledge of Hypertension Complications on Adherence to Antihypertensive Therapy
Current Hypertension Reviews Chemotherapeutic Strategies Against Trypanosoma brucei: Drug Targets vs. Drug Targeting
Current Pharmaceutical Design Gender Related Issues in the Management of Heart Failure
Current Pharmaceutical Design Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry The sdLDL Reduces MRC1 Expression Level and Secretion of Histamin e in Differentiated M2-macrophages from Patients with Coronary Artery Stenosis
Cardiovascular & Hematological Disorders-Drug Targets Prediction of Cardiovascular Risk Using Extreme Learning Machine-Tree Classifier on Apache Spark Cluster
Recent Advances in Computer Science and Communications Cardiac-Specific Expression of the Hepatocyte Growth Factor (HGF) Under the Control of a TnIc Promoter Confers a Heart Protective Effect After Myocardial Infarction (MI)
Current Gene Therapy Synthesis and Preliminary Antihyperlipidaemic Activities Evaluation of Andrographolide Derivatives
Medicinal Chemistry Pathophysiology of Necrotizing Enterocolitis: An Update
Current Pediatric Reviews Haptoglobin Phenotype Correlates with the Extent of Cerebral Deep White Matter Lesions in Hypertensive Patients
Current Neurovascular Research Current Therapeutic Strategies and Future Perspectives for the Prevention of Arterial Thromboembolism: Focus on Atrial Fibrillation
Current Pharmaceutical Design New Insight in Antiplatelet Therapy Monitoring in Cardiovascular Patients: From Aspirin to Thienopyridine
Cardiovascular & Hematological Disorders-Drug Targets Hypotensive Peptides from Snake Venoms: Structure, Function and Mechanism
Current Topics in Medicinal Chemistry Endotoxin, TLR4 Signaling and Vascular Inflammation: Potential Therapeutic Targets in Cardiovascular Disease
Current Pharmaceutical Design Metabolic Syndrome, Thyroid Function and Autoimmunity - The PORMETS Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Efficacy and Cardiovascular Safety of Alpha Glucosidase Inhibitors
Current Drug Safety The Role of Endothelin-1 in Obstructive Sleep Apnea Syndrome and Pulmonary Arterial Hypertension: Pathogenesis and Endothelin-1 Antagonists
Current Medicinal Chemistry Antiproliferative Activity of Olive Oil Phenolics against Human Melan oma Cells
Letters in Drug Design & Discovery Lipases as Modulators of Atherosclerosis in Murine Models
Current Drug Targets